Address
9704 Medical Center Drive
Rockville, MD 20850
United States of America (the)
Phone
301 251 5172
Website
Sector
Healthcare
Industry
Biotechnology
Employees
293
First IPO Date
October 10, 2013
| Name | Title | Pay | Year Born |
| Eric Blasius Risser | Chief Executive Officer, President & Director | 977,468 | 1973 |
| Thomas Spitznagel | Senior Vice President of Technical Operations | 550,974 | 1967 |
| James Karrels | Senior VP & CFO | 845,548 | 1967 |
| Ezio Bonvini | Senior Vice President of Research & Chief Scientific Officer | 881,400 | 1954 |
| Beth Smith | Vice President, Controller & Treasurer | 0 | 1968 |
| Harish Krishnaswamy | Senior Vice President of Business Development & Portfolio Planning | 0 | N/A |
| Jeffrey Stuart Peters | Senior VP, Corporate Secretary, General Counsel & Corporate Compliance Officer | 0 | 1971 |
| Frank George Perabo FEBU | Vice President & Interim Head of Clinical Development | 0 | 1964 |
| Steve Harig | Senior Vice President of Human Resources | 0 | N/A |
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.